Journal
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 85, Issue 8, Pages 923-927Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2013-307035
Keywords
-
Categories
Funding
- NIHR-Cambridge Biomedical Research Centre
- Cambridge Brain Bank and Biomedical Research Unit in Dementia
- Wellcome Trust [088324]
- NIHR
- Raymond and Beverley Sackler fellowship
- Medical Research Council
- Medical Research Council [G0001354, MC_U105597119, G1100464, G1000183B, G0001354B] Funding Source: researchfish
- National Institute for Health Research [ACF-2012-14-011] Funding Source: researchfish
- MRC [G1100464, MC_U105597119] Funding Source: UKRI
Ask authors/readers for more resources
Background Corticobasal degeneration (CBD) is a complex neurodegenerative disorder. Accurate diagnosis is increasingly important, with the advent of clinical trials of drugs aimed at modifying the underlying tau pathology. CBD often presents with a 'corticobasal syndrome' including impairments of movement and cognition. However, patients with similar corticobasal syndromes can have neurodegenerative pathologies that are not CBD. In addition, patients with CBD may present with aphasia or behavioural change. The clinical diversity of CBD and mimicry by non-CBD pathologies hinders accurate diagnosis. Methods We applied the new consensus criteria of Armstrong and colleagues et al(1) to a cohort of patients with detailed longitudinal clinical evaluation and neuropathology. Results In patients with pathologically confirmed CBD, accuracy of diagnosis was similar under the new and previous criteria: 9/19 (47%) met criteria for probable CBD at presentation, 13/19 (68%) at last clinical assessment. Patients with a corticobasal syndrome but without CBD pathology all (14/14) met the new diagnostic criteria of probable or possible CBD, demonstrating that the new criteria lacks the necessary specificity for an accurate ante mortem clinical diagnosis of CBD. None of the clinical features used in the new criteria were more common in the patients with CBD pathology (n=19) than without (n=14). Conclusions The Armstrong criteria usefully broadens the recognised clinical phenotype of CBD but does not sufficiently improve the specificity of diagnosis to increase the power of clinical trials or targeted applications of tau-based disease-modifying therapies. Further work is required to show whether biomarkers could be more effective than clinical signs in the diagnosis of CBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available